Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Birmingham, Alabama, United States
West Hollywood, California, United States
New Haven, Connecticut, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Hackensack, New Jersey, United States
New York, New York, United States
Durham, North Carolina, United States
Portland, Oregon, United States
Start Date
September 10, 2014
Primary Completion Date
February 27, 2019
Completion Date
February 27, 2019
Last Updated
April 17, 2020
83
ACTUAL participants
INCB052793
DRUG
gemcitabine
DRUG
nab-paclitaxel
DRUG
dexamethasone
DRUG
Carfilzomib
DRUG
bortezomib
DRUG
lenalidomide
DRUG
azacitidine
DRUG
INCB052793
DRUG
pomalidomide
DRUG
INCB050465
DRUG
INCB039110
DRUG
Lead Sponsor
Incyte Corporation
NCT06898450
NCT06658951
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05101070